scPharmaceuticals Inc. / Fundamentals
Income statement
- Net revenue
€42.87M - Cost of goods sold
€13.52M - Gross profit
€29.35M - SG&A expenses
€73.21M - R&D expenses
€13.23M - EBITDA
-€70.87M - D&A
-€33.46K - EBIT
-€57.09M - Interest expenses
€2.88M - EBT
-€78.69M - Tax expenses
-€6.63K - Net income
-€78.69M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€22.21M - Changes in working capital
-€5.70M - Operating cash flow
-€56.51M - Capex
€18.02K - Other investing cash flow
€0.00 - Net investing cash flow
-€18.02K - Total cash dividends paid
€0.00 - Issuance of common stock
€46.21M - Debt repayment
€0.00 - Other financing cash flow
€12.41M - Net financing cash flow
€58.50M - Foreign exchange effects
€0.00 - Net change in cash
€1.98M - Cash at end of period
€35.01M - Free cash flow
-€56.49M
Balance sheet
- Cash and cash equivalents
€35.01M - Cash and short-term investments
€35.01M - Total receivables
€16.65M - Inventory
€12.50M - Other current assets
€3.38M - Total current assets
€67.55M - Property, plant & equipment
€1.05M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€259.97K - Total non-current assets
€1.31M - Total assets
€68.86M - Accounts payable
€3.45M - Short-term debt
€226.51K - Other current liabilities
€13.85M - Total current liabilities
€17.53M - Long-term debt
€45.62M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€24.85M - Total non-current liabilities
€69.62M - Total liabilities
€87.15M - Common stock
€4.29K - Retained earnings
-€346.86M - Other equity
€0.00 - Total equity
-€18.29M - Total liabilities and shareholders' equity
€68.86M
Company information
- Market capitalization
€174.26M - Employees
162 - Enterprise Value
€210.20M
Company ratios
- Gross margin
-
68.5% Much better than peer group: -1,201.1% - EBITDA margin
-
-165.3% Much better than peer group: -10,108.5% - EBIT margin
-
-133.2% Much better than peer group: -11,140.7% - EBT margin
-
-183.5% Much better than peer group: -11,060.1% - Net margin
-
-183.5% Much better than peer group: -11,256.1% - ROE
-
430.3% Much better than peer group: -185.3% - ROA
-
-114.3% Much better than peer group: -752.2% - Asset turnover
-
62.3% Much better than peer group: 3.7% - FCF margin
-
-131.8% Much better than peer group: -9,552.9% - FCF yield
-32.4% - Efficiency ratio
265.3% - Net sales per employee
-
€264.65K - Net income per employee
-
-€485.76K